0001493152-22-026891.txt : 20220927 0001493152-22-026891.hdr.sgml : 20220927 20220927143743 ACCESSION NUMBER: 0001493152-22-026891 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20220927 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220927 DATE AS OF CHANGE: 20220927 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Immune Therapeutics, Inc. CENTRAL INDEX KEY: 0001559356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 593226705 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-54933 FILM NUMBER: 221270379 BUSINESS ADDRESS: STREET 1: 2431 ALOMA AVE #124 CITY: WINTER PARK STATE: FL ZIP: 32792 BUSINESS PHONE: (888) 613-8802 MAIL ADDRESS: STREET 1: 2431 ALOMA AVE #124 CITY: WINTER PARK STATE: FL ZIP: 32792 FORMER COMPANY: FORMER CONFORMED NAME: TNI BIOTECH, INC. DATE OF NAME CHANGE: 20121001 8-K 1 form8-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 27, 2022 (September 20, 2022)

IMMUNE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Florida

000-54933

59-3226705

(State or other jurisdiction
of incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)

2431 Aloma Ave., Suite 124, Winter Park, Florida		32792
(Address of principal executive offices)		(Zip Code)

888-391-9355

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 20, 2022, the Board of Directors (the “Board”) of Immune Therapeutics, Inc. (the “Company”), resolved to increase the size of the Board from five to six members and appoint H. Louis Salomonsky to the Board to fill the vacancy created by such increase, both effective as of September 20, 2022. The Company and Mr. Salomonsky have not entered into any arrangement regarding the payment of compensation for acting as a director of the Company.

Mr. Salomonsky is a real estate professional with decades of experience in designing, developing, and managing commercial real estate. Since June 1989, Mr. Salomonsky has been the founder and principal of Historic Housing LLC, a firm with expertise in both the adaptive reuse of historic buildings and the construction of new buildings for multi-family residential dwellings. Mr. Salomonsky’s work in the real estate market focuses on two property markets: Richmond, Virginia and Washington, D.C., where, over the past 28 years, he has created assets that Mr. Salomonsky’s firm values approximately at an aggregate $750 million. Mr. Salmonsky’s work at Historic Housing LLC specializes in federal Low-Income Housing Tax Credits and historic rehabilitation tax credits, and conventionally-financed three- to twelve-story new-construction buildings. Mr. Salmonsky’s experience also includes community and professional volunteer work, including serving on task forces to examine historic tax credit legislation for the Commonwealth of Virginia and regarding government structure for the City of Richmond. Mr. Salomonsky served as the Vice Rector and as a Member of the Board of Visitors for Virginia State University. Mr. Salomonsky is currently serving on the University of Virginia School of Architecture Foundation Board, of which he has been a director since July 1, 2020. Our Board believes that Mr. Salomonsky is qualified to serve as a member of the Board due to his many years of operational leadership and his previous board memberships. Mr. Salomonsky was appointed to serve on the Board until his successor is duly elected and qualified. There are no arrangements or understandings between Mr. Salomonsky and any other persons pursuant to which he was selected as a director. There has been no transaction, nor is there any currently proposed transaction, between Mr. Salomonsky and the Company that would require disclosure under Item 404(a) of Regulation S-K.

Item 8.01 Other Events.

On September 27, 2022, the Company issued a press release announcing the appointment of Mr. Salomonsky to the Board. A copy of the press release is attached to this report as Exhibit 99.1. The press release furnished in this report as Exhibit 99.1 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description of Exhibit
99.1		Press Release dated September 27, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 27, 2022	IMMUNUNE THERAPEUTICES, INC.

		/s/ Stephen Wilson
	Name:	Dr. Stephen Wilson
	Title:	Chief Executive Officer

3

EX-99.1 2 ex99-1.htm

Exhibit 99.1

Immune Therapeutics Appoints H. Louis Salomonksy to its Board of Directors

ORLANDO, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) — Immune Therapeutics, Inc. (OTC PINK:IMUN) (“Immune” or “IMUN”), a specialty pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products with a well-defined path to market, today announced the appointment of Louis Salomonsky to the Company’s Board of Directors.

“On behalf of the Board and leadership of Immune, I would like to welcome Louis to Immune’s Board,” said Dr. Stephen Wilson, CEO of Immune. “Mr. Salomonsky’s operational leadership, as well as his track record of deal-making and financial acumen, will be instrumental in moving our programs forward.”

Commenting on his appointment, Mr. Salomonsky said, “I am excited to join Immune’s Board to help advance the company’s cutting-edge research and emerging pipeline of immune-modulating and immuno-restorative therapeutics. I look forward to working with this seasoned team and, alongside other fresh perspectives from the members of our Board, I believe we now have the opportunity to rapidly develop Immune’s research and commercial pipeline.”

About Mr. Salomonsky

Louis Salomonsky is a real estate professional with decades of experience designing, developing, and managing commercial real estate. Mr. Salomonsky’s firm, Historic Housing LLC, has expertise in the adaptive reuse of historic buildings, as well as the construction of new buildings for multi-family residential. Mr. Salomonsky works in two dynamic property markets, namely Richmond, Virginia and Washington, DC, creating assets collectively valued by Mr. Salomonsky’s firm at $750 million, over the past 28 years. Mr. Salomonsky’s firm specializes in federal Low-Income Housing Tax Credits and historic rehabilitation tax credits, and conventionally financed three to twelve-story market rate new-construction buildings.

Mr. Salomonsky has a long track record of community and professional volunteerism including serving on task forces examining historic tax credit legislation for the Commonwealth of Virginia and the government structure of the City of Richmond. Mr. Salomonsky has served as the Vice Rector and as a Member of the Board of Visitors for Virginia State University. He currently serves on the UVA School of Architecture Foundation Board.

About Immune Therapeutics, Inc.

Immune Therapeutics, Inc. is a pioneering pharmaceutical company involved in the acquisition, development, and commercialization of pharmaceutical and biotechnology products that have a well-defined path to market. By utilizing a biotech portfolio hub-and-spoke engine, we plan to advance focused and efficient small-scale biotechnology and pharmaceutical programs through subsidiaries, investment vehicles or partnerships, and deploy products from those programs in markets both in the U.S. and internationally for initial commercialization.

Forward Looking Statement

This press release may contain information about our views of future expectations, plans and prospects that constitute forward-looking statements. All forward-looking statements are based on management’s beliefs, assumptions, and expectations of Immune’s future economic performance, taking into account the information currently available to it. These statements are not statements of historical fact. Although Immune believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Immune does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. No assurances can be made that Immune will successfully acquire its acquisition targets. Forward-looking statements are subject to a number of factors, risks, and uncertainties, some of which are not currently known to us, that may cause Immune’s actual results, performance, or financial condition to be materially different from the expectations of future results, performance, or financial position. Actual results may differ materially from the expectations discussed in forward-looking statements. Factors that could cause actual results to differ materially from expectations include general industry considerations, regulatory review and approval of our prospective products, changes in local or national economic conditions and other risks set forth in “Risk Factors” included in our filings with the Securities and Exchange Commission.

Disclaimer

The information provided in this press release is intended for general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition. This information is not intended to diagnose, treat, cure or prevent any disease.

Contact:

Dr. Stephen Wilson

CEO

ir@immunetherapeutics.com

1-888-391-9355

www.immunetherapeutics.com

EX-101.SCH 3 imun-20220927.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 imun-20220927_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 imun-20220927_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	Sep. 27, 2022
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 27, 2022
Entity File Number	000-54933
Entity Registrant Name	IMMUNE THERAPEUTICS, INC.
Entity Central Index Key	0001559356
Entity Tax Identification Number	59-3226705
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2431 Aloma Ave.
Entity Address, Address Line Two	Suite 124
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	888
Local Phone Number	391-9355
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	false

XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001559356 2022-09-27 2022-09-27 iso4217:USD shares iso4217:USD shares 0001559356 false 8-K 2022-09-27 IMMUNE THERAPEUTICS, INC. FL 000-54933 59-3226705 2431 Aloma Ave. Suite 124 Winter Park FL 32792 888 391-9355 false false false false false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 20 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://immunetherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm imun-20220927.xsd imun-20220927_lab.xml imun-20220927_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "imun-20220927_lab.xml" ] }, "presentationLink": { "local": [ "imun-20220927_pre.xml" ] }, "schema": { "local": [ "imun-20220927.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "IMUN", "nsuri": "http://immunetherapeutics.com/20220927", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-09-27to2022-09-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://immunetherapeutics.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-09-27to2022-09-27", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://immunetherapeutics.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 14 0001493152-22-026891-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-026891-xbrl.zip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end